Cost‐utility of once‐weekly insulin icodec versus once‐daily basal insulins for type 2 diabetes in China
Once-weekly icodec represents a cost-effective and clinically beneficial alternative to once-daily basal insulin analogues for Chinese adults with type 2 diabetes within the current reimbursement framework.
Authors
- Xichen Tong
- Chang Xing
- Lei Zhang
- Luying Zhang
Institutions
- Fudan University (CN)
- Wuhan University (CN)
- Wuhan Donghu University (CN)
- Novo Nordisk (Switzerland) (CH)
- Novo Nordisk (Italy) (IT)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-02-18
- DOI
- https://doi.org/10.1111/dom.70567
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Novo Nordisk